Achieve Life Sciences (NASDAQ:ACHV) Now Covered by Jonestrading

Jonestrading started coverage on shares of Achieve Life Sciences (NASDAQ:ACHV) in a note issued to investors on Wednesday, Benzinga reports. The brokerage set a “buy” rating and a $20.00 price target on the biopharmaceutical company’s stock. Jonestrading’s price target would indicate a potential upside of 337.64% from the company’s current price.

Several other equities analysts have also recently commented on ACHV. Lake Street Capital reduced their price objective on shares of Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, March 5th. Oppenheimer reiterated an “outperform” rating and set a $18.00 target price on shares of Achieve Life Sciences in a research report on Monday, April 1st.

Achieve Life Sciences Price Performance

Shares of NASDAQ:ACHV opened at $4.57 on Wednesday. The company has a 50 day moving average of $4.42 and a 200 day moving average of $4.40. The stock has a market cap of $156.53 million, a P/E ratio of -2.99 and a beta of 1.32. Achieve Life Sciences has a 12 month low of $3.03 and a 12 month high of $10.30. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 4.02.

Institutional Investors Weigh In On Achieve Life Sciences

Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Achieve Life Sciences by 75.6% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,646 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 1,570 shares during the last quarter. HRT Financial LP bought a new stake in shares of Achieve Life Sciences in the 4th quarter worth approximately $32,000. Morgan Stanley lifted its holdings in shares of Achieve Life Sciences by 437.4% in the 4th quarter. Morgan Stanley now owns 13,547 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 11,026 shares during the last quarter. Madison Park Capital Advisors LLC bought a new stake in shares of Achieve Life Sciences in the 4th quarter worth approximately $41,000. Finally, Prelude Capital Management LLC bought a new stake in shares of Achieve Life Sciences in the 2nd quarter worth approximately $49,000. 33.52% of the stock is currently owned by institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.